10x Genomics: Atera Orders Outpace Guidance, AI Tailwind Widens

A long-awaited platform launch and an AI-driven demand shift are finally re-rating a beaten-down genomics name.

TXG · Earnings Call · 2026-08-06

A Long-Awaited Re-Rating

After a brutal multi-year drawdown, 10x Genomics is suddenly in motion: the stock is up ~180% over the last 90 days, off a low that had pushed it to roughly $3B in market cap. The catalyst is not subtle. The company's new spatial platform, Atera instrument, has generated demand that management candidly says exceeded even their own high expectations. In the Q2 2026 call, Serge Saxonov put it plainly: “the demand has been extraordinary. And that's not the constraint here, right? The constraint is actually shifting the manufacturing capacity to ship the units in the second half of the year.” — Serge Saxonov, CEO · 2026-08-06 That demand has translated into a concrete leading indicator: “As of the end of the second quarter, booked orders already greatly exceeded that full year number” — Adam Taich, CFO · 2026-08-06 — the full-year target of ~40 instruments. The company is deliberately holding shipments to ~40 units while production ramps, but the order book implies a much larger installed base is coming. This is a classic supply-constrained launch, and the stock's recent move reflects the market pricing in that latent upside.

The promise of spatial has always been that it represents the convergence of molecular, cell, and tissue biology. Atera is poised to deliver on that promise to provide researchers with a fundamentally more complete view of biological systems and answers to many questions that were previously out of reach.
Serge Saxonov, CEO · 2026-08-06

Beyond Atera: AI and the Research Landscape

Atera is not the only story. The company is increasingly positioning itself at the nexus of AI-driven biology. In the current call, Serge emphasized how the demand for high-quality biological data is being amplified by AI: “AI, as an influencer of demand, is now becoming pervasive across our customer base.” — Serge Saxonov, CEO · 2026-08-06 This is a theme the company has been building for several quarters — in the February 2026 call, he stated “We fundamentally believe and are seeing that AI is a structural tailwind to our business.” — Serge Saxonov, Chief Executive Officer · 2026-05-07 The difference now is that the tailwind is starting to show up in order flow, particularly for the Flex Apex assay, which has become the standard for large-scale perturbation screens. The company also made a strategic move to deepen its multi-omics offering with the Proteintech Genomics acquisition. This expands Atera's roadmap to include protein measurements alongside spatial transcriptomics, a combination that management believes will keep the platform ahead of the curve.

Financial and Valuation Implications

Financially, the company is still small and unprofitable on a GAAP basis, but the trajectory is improving. Gross margins expanded to 74% in Q2 (ex-settlement) and the company raised full-year guidance to $610–$630M, implying a meaningful Q4 step-up as Atera shipments begin. The balance sheet is solid with $552M in cash, giving it runway to invest through the launch. Despite the recent rally, the valuation remains historically low. The stock trades at roughly 0.3x Price-to-Revenue, a fraction of the multiple it commanded at the peak of the genomics boom. This reflects both the deep discount the market had applied and the uncertainty around the timing of Atera's contribution. But with demand outrunning supply, the setup for 2027 is unusually compelling. The key risk, as always, is the academic funding environment. Management noted that sentiment has improved but dollars are still not flowing: “The dollars are still not flowing out, at least as far as the spending decisions are concerned.” — Serge Saxonov, CEO · 2026-08-06 That said, the AI-driven demand is increasingly coming from biopharma and large academic consortia that are less exposed to the NIH volatility. If that trend holds, 10x could finally be at the beginning of a sustainable upcycle.